Search

Your search keyword '"Usmani, Saad Z"' showing total 1,254 results
Start Over Author "Usmani, Saad Z" Publication Year Range Last 10 years
1,254 results on '"Usmani, Saad Z"'

3. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

Author

Maura, Francesco, Boyle, Eileen M., Coffey, David, Maclachlan, Kylee, Gagler, Dylan, Diamond, Benjamin, Ghamlouch, Hussein, Blaney, Patrick, Ziccheddu, Bachisio, Cirrincione, Anthony, Chojnacka, Monika, Wang, Yubao, Siegel, Ariel, Hoffman, James E., Kazandjian, Dickran, Hassoun, Hani, Guzman, Emily, Mailankody, Sham, Shah, Urvi A., Tan, Carlyn, Hultcrantz, Malin, Scordo, Michael, Shah, Gunjan L., Landau, Heather, Chung, David J., Giralt, Sergio, Zhang, Yanming, Arbini, Arnaldo, Gao, Qi, Roshal, Mikhail, Dogan, Ahmet, Lesokhin, Alexander M., Davies, Faith E., Usmani, Saad Z., Korde, Neha, Morgan, Gareth J., and Landgren, Ola

Published
2023
Full Text
View/download PDF

4. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Author

Shah, Urvi A, Maclachlan, Kylee H, Derkach, Andriy, Salcedo, Meghan, Barnett, Kelly, Caple, Julia, Blaslov, Jenna, Tran, Linh, Ciardiello, Amanda, Burge, Miranda, Shekarkhand, Tala, Adintori, Peter, Cross, Justin, Pianko, Matthew J, Hosszu, Kinga, McAvoy, Devin, Mailankody, Sham, Korde, Neha, Hultcrantz, Malin, Hassoun, Hani, Tan, Carlyn R, Lu, Sydney X, Patel, Dhwani, Diamond, Benjamin, Shah, Gunjan, Scordo, Michael, Lahoud, Oscar, Chung, David J, Landau, Heather, Usmani, Saad Z, Giralt, Sergio, Taur, Ying, Landgren, C Ola, Block, Gladys, Block, Torin, Peled, Jonathan U, van den Brink, Marcel RM, and Lesokhin, Alexander M

Subjects
Nutrition, Rare Diseases, Complementary and Integrative Health, Clinical Research, Cancer, Hematology, Oral and gastrointestinal, Good Health and Well Being, Humans, Multiple Myeloma, Butyrates, Neoplasm, Residual, Diet, Healthy, Diet, Vegetarian, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeSustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We hypothesized that dietary factors affect the microbiome (abundance of butyrate-producing bacteria or stool butyrate concentration) and may be associated with multiple myeloma outcomes.Experimental designWe examined the relationship of dietary factors (via a food frequency questionnaire), stool metabolites (via gas chromatography-mass spectrometry), and the stool microbiome (via 16S sequencing - α-diversity and relative abundance of butyrate-producing bacteria) with sustained MRD negativity (via flow cytometry at two timepoints 1 year apart) in myeloma patients on lenalidomide maintenance. The Healthy Eating Index 2015 score and flavonoid nutrient values were calculated from the food frequency questionnaire. The Wilcoxon rank sum test was used to evaluate associations with two-sided P < 0.05 considered significant.ResultsAt 3 months, higher stool butyrate concentration (P = 0.037), butyrate producers (P = 0.025), and α-diversity (P = 0.0035) were associated with sustained MRD negativity. Healthier dietary proteins, (from seafood and plants), correlated with butyrate at 3 months (P = 0.009) and sustained MRD negativity (P = 0.05). Consumption of dietary flavonoids, plant nutrients with antioxidant effects, correlated with stool butyrate concentration (anthocyanidins P = 0.01, flavones P = 0.01, and flavanols P = 0.02).ConclusionsThis is the first study to demonstrate an association between a plant-based dietary pattern, stool butyrate production, and sustained MRD negativity in multiple myeloma, providing rationale to evaluate a prospective dietary intervention.

Published
2022

5. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Clinical Research, Vaccine Related, Clinical Trials and Supportive Activities, Biotechnology, Rare Diseases, Hematology, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

6. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Author

Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad Z., Bahlis, Nizar J., van de Donk, Niels W. C. J., and Verona, Raluca I.

Published
2024
Full Text
View/download PDF

8. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Author

Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, and Girgis, Suzette

Published
2023
Full Text
View/download PDF

10. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Author

Hamadeh, Issam S., Shekarkhand, Tala, Rueda, Colin, Firestone, Ross S., Wang, Alice X., Korde, Neha, Hultcrantz, Malin L., Lesokhin, Alexander M., Mailankody, Sham, Hassoun, Hani, Shah, Urvi A., Maclachlan, Kylee, Rajeeve, Sridevi, Patel, Dhwani, Shah, Gunjan L., Scordo, Michael, Lahoud, Oscar B., Chung, David J., Landau, Heather J., Giralt, Sergio, Usmani, Saad Z., and Tan, Carlyn R.

Published
2024
Full Text
View/download PDF

11. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Author

Howard, Anna J., Concepcion, Isabel, Wang, Alice X., Hamadeh, Issam S., Hultcrantz, Malin, Mailankody, Sham, Tan, Carlyn, Korde, Neha, Lesokhin, Alexander M., Hassoun, Hani, Shah, Urvi A., Maclachlan, Kylee H., Rajeeve, Sridevi, Landau, Heather J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar B., Chung, David J., Giralt, Sergio, Usmani, Saad Z., and Firestone, Ross S.

Published
2024
Full Text
View/download PDF

13. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Author

Firestone, Ross S., McAvoy, Devin, Shekarkhand, Tala, Serrano, Edith, Hamadeh, Issam, Wang, Alice, Zhu, Menglei, Qin, Wei Ge, Patel, Dhwani, Tan, Carlyn R., Hultcrantz, Malin, Mailankody, Sham, Hassoun, Hani, Shah, Urvi S., Korde, Neha, Maclachlan, Kylee H., Landau, Heather J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar B., Giralt, Sergio, Murata, Kazunori, Hosszu, Kinga K., Chung, David J., Lesokhin, Alexander M., and Usmani, Saad Z.

Published
2024
Full Text
View/download PDF

16. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Author

Tan, Carlyn Rose, Derkach, Andriy, Nemirovsky, David, Ciardiello, Amanda, Diamond, Benjamin, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi, Maclachlan, Kylee, Patel, Dhwani, Lahoud, Oscar B., Landau, Heather J., Chung, David J., Shah, Gunjan L., Scordo, Michael, Giralt, Sergio A., Lesokhin, Alexander, Usmani, Saad Z., Landgren, Ola, and Korde, Neha

Published
2023
Full Text
View/download PDF

19. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

Author

Martin, Thomas G., Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred, Mateos, María-Victoria, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Krishnan, Amrita, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Delforge, Michel, Trancucci, Danielle, Pei, Lixia, Kobos, Rachel, Fastenau, John, Gries, Katharine S., and van de Donk, Niels W.C.J.

Published
2024
Full Text
View/download PDF

21. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Author

Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z., Yoon, Sung-Soo, Usmani, Saad Z., Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J. Blake, Carson, Robin, and Dimopoulos, Meletios A.

Published
2024
Full Text
View/download PDF

22. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Author

Shah, Urvi A., Moshier, Erin, Derkach, Andriy, Huang, Yuanhui, Mailankody, Sham, Tan, Carlyn R., Maclachlan, Kylee, Hultcrantz, Malin, Korde, Neha, Hassoun, Hani, Thibaud, Santiago, Sanchez, Larysa, Rodriguez, Cesar, Richard, Shambavi, Richter, Joshua, Rossi, Adriana, Cho, Hearn Jay, Lesokhin, Alexander, Chari, Ajai, Usmani, Saad Z., Jagannath, Sundar, Parekh, Samir, and Gallagher, Emily J.

Published
2024
Full Text
View/download PDF

23. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Author

Gordan, Lucio Navarro, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex Z., Lafeuille, Marie-Hélène, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, and Usmani, Saad Z.

Published
2024
Full Text
View/download PDF

24. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Author

Holstein, Sarah A, Bahlis, Nizar, Bergsagel, P Leif, Bhutani, Manisha, Bolli, Niccolo, Brownstein, Carrie, Demolis, Pierre, Foureau, David, Gay, Francesca, Ghobrial, Irene M, Gormley, Nicole, Hillengass, Jens, Kaiser, Martin, Maus, Marcela V, Melenhorst, J Joseph, Merz, Maximilian, Dwyer, Michael O, Paiva, Bruno, Pasquini, Marcelo C, Shah, Nina, Wong, Sandy W, Usmani, Saad Z, and McCarthy, Philip L

Subjects
Transplantation, Rare Diseases, Cancer, Hematology, Good Health and Well Being, Humans, Bone Marrow, Diterpenes, High-Throughput Nucleotide Sequencing, Multiple Myeloma, Neoplasm, Residual, Minimal residual disease, Immune profiling, Multiple myeloma, Endpoint, CAR T-cell, Cellular therapy
Abstract

The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.

Published
2021

30. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Author

Voorhees, Peter M, Sborov, Douglas W, Laubach, Jacob, Kaufman, Jonathan L, Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J, Anderson, Larry D, Jr, Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Efebera, Yvonne A, Holstein, Sarah A, Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M, Orlowski, Robert Z, Shain, Kenneth H, Cowan, Andrew J, Dinner, Shira, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S, Usmani, Saad Z, and Richardson, Paul G

Published
2023
Full Text
View/download PDF

31. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Author

Terpos, Evangelos, Mikhael, Joseph, Hajek, Roman, Chari, Ajai, Zweegman, Sonja, Lee, Hans C, Mateos, María-Victoria, Larocca, Alessandra, Ramasamy, Karthik, Kaiser, Martin, Cook, Gordon, Weisel, Katja C, Costello, Caitlin L, Elliott, Jennifer, Palumbo, Antonio, and Usmani, Saad Z

Subjects
Comparative Effectiveness Research, Health Services, Rare Diseases, Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Hematology, Orphan Drug, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Agents, Clinical Trials, Phase III as Topic, Disease Management, Humans, Multiple Myeloma, Quality of Life, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis
Abstract

Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the 'efficacy' of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual's composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting.

Published
2021

33. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

Author

Bhutani, Manisha, Foureau, David M., Robinson, Myra, Guo, Fei, Fesenkova, Kateryna, Atrash, Shebli, Paul, Barry, Varga, Cindy, Friend, Reed, Pineda-Roman, Mauricio, Rigby, Katherine, Symanowski, James T., Norek, Sarah, Tucker, Mallory R., Druhan, Lawrence J., Voorhees, Peter M., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

34. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

Author

Mateos, María-Victoria, Chari, Ajai, Usmani, Saad Z., Goldschmidt, Hartmut, Weisel, Katja, Qi, Keqin, Londhe, Anil, Nair, Sandhya, Lin, Xiwu, Pei, Lixia, Ammann, Eric, Kobos, Rachel, Smit, Jennifer, Parekh, Trilok, Marshall, Alexander, Slavcev, Mary, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

35. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

Author

Shah, Nina, Chari, Ajai, Scott, Emma, Mezzi, Khalid, and Usmani, Saad Z

Subjects
Rare Diseases, Clinical Research, Orphan Drug, Biotechnology, Cancer, Hematology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, B-Lymphocytes, Biomarkers, Tumor, Clinical Trials as Topic, Drug Resistance, Neoplasm, Gene Expression, Humans, Immunoconjugates, Immunotherapy, Adoptive, Molecular Targeted Therapy, Multiple Myeloma, Recurrence, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there is no cure for MM, patients eventually become resistant to therapies, leading to development of relapsed/refractory MM. Therefore, an unmet need exists for MM treatments with novel mechanisms of action that can provide durable responses, evade resistance to prior therapies, and/or are better tolerated. B-cell maturation antigen (BCMA) is preferentially expressed by mature B lymphocytes, and its overexpression and activation are associated with MM in preclinical models and humans, supporting its potential utility as a therapeutic target for MM. Moreover, the use of BCMA as a biomarker for MM is supported by its prognostic value, correlation with clinical status, and its ability to be used in traditionally difficult-to-monitor patient populations. Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody-drug conjugates, and chimeric antigen receptor (CAR)-modified T-cell therapy. We provide an overview of preliminary clinical data from trials using these therapies, including the BiTE® (bispecific T-cell engager) immuno-oncology therapy AMG 420, the antibody-drug conjugate GSK2857916, and several CAR T-cell therapeutic agents including bb2121, NIH CAR-BCMA, and LCAR-B38M. Notable antimyeloma activity and high minimal residual disease negativity rates have been observed with several of these treatments. These clinical data outline the potential for BCMA-targeted therapies to improve the treatment landscape for MM. Importantly, clinical results to date suggest that these therapies may hold promise for deep and durable responses and support further investigation in earlier lines of treatment, including newly diagnosed MM.

Published
2020

36. Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations

Author

Maclachlan, Kylee H., Bagratuni, Tina, Kastritis, Efstathios, Ziccheddu, Bachisio, Lu, Sydney, Yellapantula, Venkata, Famulare, Chris, Argyropoulos, Kimon, Derkach, Andriy, Papaemmanuil, Elli, Dogan, Ahmet, Lesokhin, Alexander, Usmani, Saad Z., Landgren, C. Ola, Palomba, Lia M., Maura, Francesco, and Dimopoulos, Meletios A.

Published
2023
Full Text
View/download PDF

37. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study

Author

Korde, Neha, Tavitian, Elizabet, Mastey, Donna, Lengfellner, Joseph, Hevroni, Gil, Zarski, Andrew, Salcedo, Meghan, Mailankody, Sham, Hassoun, Hani, Smith, Eric L., Hultcrantz, Malin, Shah, Urvi, Tan, Carlyn, Diamond, Benjamin, Shah, Gunjan, Scordo, Michael, Lahoud, Oscar, Chung, David J., Landau, Heather, Giralt, Sergio, Derkach, Andriy, Atkinson, Thomas M., Sabbatini, Paul, König, Francesca, Usmani, Saad Z., Landgren, Ola, and Lesokhin, Alexander M.

Published
2023
Full Text
View/download PDF

38. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Author

Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, van Rhee, Frits, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hájek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesus G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, and Chari, Ajai

Published
2023
Full Text
View/download PDF

39. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

41. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

Author

Cohen, Adam D., Hari, Parameswaran, Htut, Myo, Berdeja, Jesus G., Usmani, Saad Z., Madduri, Deepu, Olyslager, Yunsi, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Gries, Katharine S., Fastenau, John M., Valluri, Satish, Deraedt, William, Akram, Muhammad, Crawford, Rebecca, Morrison, Ross, Doward, Lynda, Morgan, Kate, Seldam, Silene ten, Jakubowiak, Andrzej, and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

42. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

Author

Costa, Bruno Almeida, primary, Flynn, Jessica, additional, Nishimura, Noriko, additional, Devlin, Sean M., additional, Farzana, Tasmin, additional, Rajeeve, Sridevi, additional, Chung, David J., additional, Landau, Heather J., additional, Lahoud, Oscar B., additional, Scordo, Michael, additional, Shah, Gunjan L., additional, Hassoun, Hani, additional, Maclachlan, Kylee, additional, Hultcrantz, Malin, additional, Korde, Neha, additional, Lesokhin, Alexander M., additional, Shah, Urvi A., additional, Tan, Carlyn R., additional, Giralt, Sergio A., additional, Usmani, Saad Z., additional, Nath, Karthik, additional, and Mailankody, Sham, additional

Published
2024
Full Text
View/download PDF

43. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1

Author

Cortes-Selva, Diana, primary, Perova, Tatiana, additional, Skerget, Sheri, additional, Vishwamitra, Deeksha, additional, Stein, Sarah, additional, Boominathan, Rengasamy, additional, Lau, On Say, additional, Nielsen, Karl, additional, Davis, Cuc, additional, Patel, Jaymala H, additional, Banerjee, Arnob, additional, Stephenson, Tara, additional, Uhlar, Clarissa, additional, Kobos, Rachel, additional, Goldberg, Jenna D., additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Wu, Liviawati S., additional, Moreau, Philippe, additional, Usmani, Saad Z, additional, Bahlis, Nizar J, additional, van de Donk, Niels W.C.J., additional, and Verona, Raluca, additional

Published
2024
Full Text
View/download PDF

44. Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN

Author

Silbermann, Rebecca, primary, Laubach, Jacob, additional, Kaufman, Jonathan L., additional, Sborov, Douglas W., additional, Reeves, Brandi, additional, Rodriguez, Cesar, additional, Chari, Ajai, additional, Costa, Luciano J., additional, Anderson, Larry D., additional, Nathwani, Nitya, additional, Shah, Nina, additional, Bumma, Naresh, additional, Holstein, Sarah A., additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Orlowski, Robert Z., additional, Shain, Kenneth H., additional, Cowan, Andrew J., additional, Gries, Katharine S., additional, Pei, Huiling, additional, Cortoos, Annelore, additional, Patel, Sharmila, additional, Lin, Thomas S., additional, Voorhees, Peter M., additional, Usmani, Saad Z., additional, and Richardson, Paul G., additional

Published
2024
Full Text
View/download PDF

45. Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies

Author

Howard, Anna J, primary, Concepcion, Isabel, additional, Wang, Alice X., additional, Hamadeh, Issam S., additional, Hultcrantz, Malin L., additional, Mailankody, Sham, additional, Tan, Carlyn Rose, additional, Korde, Neha, additional, Lesokhin, Alexander M., additional, Hassoun, Hani, additional, Shah, Urvi A., additional, Maclachlan, Kylee H., additional, Rajeeve, Sridevi, additional, Landau, Heather J., additional, Scordo, Michael, additional, Shah, Gunjan L, additional, Lahoud, Oscar B, additional, Chung, David J., additional, Giralt, Sergio A, additional, Usmani, Saad Z, additional, and Firestone, Ross S., additional

Published
2024
Full Text
View/download PDF

46. Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy

Author

Hamadeh, Issam S., primary, Shekarkhand, Tala, additional, Rueda, Colin Joseph, additional, Firestone, Ross S., additional, Wang, Alice X., additional, Korde, Neha, additional, Hultcrantz, Malin L., additional, Lesokhin, Alexander M., additional, Mailankody, Sham, additional, Hassoun, Hani, additional, Shah, Urvi A., additional, Maclachlan, Kylee H., additional, Rajeeve, Sridevi, additional, Patel, Dhwani, additional, Shah, Gunjan L, additional, Scordo, Michael, additional, Lahoud, Oscar B, additional, Chung, David J., additional, Landau, Heather J., additional, Giralt, Sergio A, additional, Usmani, Saad Z, additional, and Tan, Carlyn Rose, additional

Published
2024
Full Text
View/download PDF

47. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy

Author

Hashmi, Hamza, primary, Kumar, Ambuj, additional, Kharfan-Dabaja, Mohamed A., additional, Munshi, Pashna N., additional, Inamoto, Yoshihiro, additional, DeFilipp, Zachariah M., additional, Dholaria, Bhagirathbhai, additional, Jain, Tania, additional, Perales, Miguel-Angel, additional, Carpenter, Paul A., additional, Hamadani, Mehdi, additional, Dhakal, Binod, additional, and Usmani, Saad Z., additional

Published
2024
Full Text
View/download PDF

48. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Author

Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

50. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

Author

Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D, Htut, Myo, Stewart, A Keith, Hari, Parameswaran, Berdeja, Jesus G, Usmani, Saad Z, Yeh, Tzu-Min, Olyslager, Yunsi, Goldberg, Jenna D, Schecter, Jordan M, Madduri, Deepu, Jackson, Carolyn C, Deraedt, William, Gries, Katharine S, Fastenau, John M, Trudeau, Jeremiah J, Akram, Muhammad, Pacaud, Lida, Jakubowiak, Andrzej, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results